Search - tctmd.com

Displaying 61 - 80 of 306

Sort: Relevancy | Date

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

December 05, 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

November 13, 2024

TCT 304: SGLT2 Inhibitor Empagliflozin Before Coronary Angiography: Can We Reduce Patient Stress?

Presentation TCT 2024

TCT 304: SGLT2 Inhibitor Empagliflozin Before Coronary Angiography: Can We Reduce Patient Stress?

Presenter: Katica Cvitkusic Lukenda

October 27, 2024

TCT 185: Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Presentation TCT 2024

TCT 185: Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Presenter: Samarthkumar Thakkar

October 27, 2024

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

October 23, 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

News Daily News

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Michael O'Riordan

September 24, 2024

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

September 20, 2024

Little Pre- and Postmarket Testing for Most Recalled CV Devices

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

ACC/AHA Clarify How Social Determinants of Health Impact CVD

News Daily News

ACC/AHA Clarify How Social Determinants of Health Impact CVD

August 28, 2024

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

News Daily News

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

August 13, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.